Skip to main navigation
Liquidia Logo
Skip to main content
Liquidia Logo

    Home

  • Home

    • About

  • About Liquidia
    • Overview
    • Leadership
    • Board of Directors

    • Products and Pipeline

  • Pipeline and Products
    • Pipeline
    • Commercial Products
    • PRINT® Technology
    • Publications

    • IR Nav

  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • IR Resources
      • Investor FAQs
      • IR Contact
      • Email Alerts
      • Proxy Online

    • Careers

  • Careers
    • Overview
    • Jobs
    • Benefits
    • Principles

    • Contact Us

  • Contact Us
    • Overview
    • Map/Directions

Event

IR Nav

Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
    Analyst Coverage Stock Quote & Chart Historical Price Lookup Investment Calculator
  • Corporate Governance
    Documents & Charters Leadership Board of Directors Committee Composition
  • SEC Filings
  • IR Resources
    Investor FAQs IR Contact Email Alerts Proxy Online

Jefferies London Healthcare Conference (Virtual)

Nov 18, 2021 at 8:00 AM GMT

Click here for webcast

IR Tools

  • Print Page
  • Share
  • RSS
Liquidia Logo

419 Davis Drive, Suite 100, Morrisville, NC 27560
Tel +1 919-328-4400
Fax +1 919-328-4402

Socials

© 2023 Liquidia Corporation All Rights Reserved.

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection.

Legal Nav

  • Legal
  • Privacy
  • Cookies
  • Social Media
  • Facebook
  • Twitter
  • LinkedIn